Trial · NCT03193190
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | 37.5 | 95% Confidence Interval 21.10 to 56.31 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | 55.6 | 95% Confidence Interval 21.20 to 86.30 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | 48.0 | 95% Confidence Interval 27.80 to 68.69 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | 26.7 | 95% Confidence Interval 7.79 to 55.10 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | 31.7 | 95% Confidence Interval 18.08 to 48.09 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | 30.0 | 95% Confidence Interval 14.73 to 49.40 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | 8.7 | 95% Confidence Interval 1.07 to 28.04 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | 0 | 95% Confidence Interval 0.00 to 14.82 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | 0 | 95% Confidence Interval 0.00 to 23.16 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | 0 | 95% Confidence Interval 0.00 to 23.16 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | 6.1 | 95% Confidence Interval 1.68 to 14.80 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | 0 | 95% Confidence Interval 0.00 to 21.80 | percentage of participants | |
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | 7.1 | 95% Confidence Interval 0.18 to 33.87 | percentage of participants | |
| Number of Participants With Adverse Events (AEs) | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | 32 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | 9 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | 24 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | 15 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | 41 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | 30 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | 22 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03193190/results